Impact of oral osteoarthritis therapy usage among other risk factors on knee replacement: a nested case-control study using the Osteoarthritis Initiative cohort

Marc Dorais¹, Johanne Martel-Pelletier², Jean-Pierre Raynauld², Philippe Delorme² and Jean-Pierre Pelletier²*

Abstract

Background: The aim of this study was to measure the association between exposure to commonly used oral osteoarthritis (OA) therapies and relevant confounding risk factors on the occurrence of knee replacement (KR), using the Osteoarthritis Initiative (OAI) database.

Methods: In this nested case-control design study, participants who had a KR after cohort entry were defined as “cases” and were matched with up to four controls for age, gender, income, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain, Kellgren-Lawrence grade, and duration of follow up. Exposure to oral OA therapies (acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 (COX-2) inhibitors, narcotics, and glucosamine/chondroitin sulfate) was determined within the 3 years prior to the date of the KR. Conditional regression analyses were performed to estimate the association between KR and exposure to oral OA therapies and other potential confounding risk factors.

Results: A total of 218 participants who underwent a KR (cases) were matched to 540 controls. The median time to KR was 4.3 years among cases. The majority in both groups were Caucasian with mean age of 69 years and 61% were female. Numerically, cases were more exposed to acetaminophen, NSAIDs, and COX-2 inhibitors. Exposure to narcotics and glucosamine/chondroitin sulfate was relatively similar between cases and controls. No significant association was found between the occurrence of KR and exposure to any of the oral OA therapies within the 3 years prior to KR. A significantly higher occurrence of KR was found in Caucasian subjects (OR 1.84; 95% CI, 1.13–2.99; p = 0.015) and subjects with body mass index (BMI) ≥ 27 kg/m² (OR 1.65; 95% CI, 1.06–2.58; p = 0.027).

Conclusion: This study provides evidence that the main risk factors leading to KR are disease severity, symptoms and high BMI. Importantly, exposure to oral OA therapies was not associated with the occurrence of KR.

Keywords: Nested case-control, Osteoarthritis, Osteoarthritis Initiative, Knee replacement, Acetaminophen, NSAIDs, Coxibs, Narcotics, Glucosamine/chondroitin sulfate

* Correspondence: dr@jppelletier.ca
²Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Quebec, Canada

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Osteoarthritis (OA) is one of the arthritis conditions most often associated with chronic pain and disability [1]. As such, patients with OA are in need of treatment that includes a number of different pharmacological classes of agents. They are most commonly oral agents and are very often prescribed for chronic administration over an extended period of time. In recent years there has been concern about the safety of some of drug treatments, mainly related to potential detrimental systemic effects such as cardiovascular risks and morbidity associated, for instance, with non-steroidal anti-inflammatory drugs (NSAIDs) and coxibs [2]. Moreover, the use of narcotics by patients with OA has also been associated with an increased risk of morbidity and even mortality [3]. Concerns have also been raised about the effects of these drug treatments on the evolution of OA structural changes, particularly in weight-bearing joints such as the hip and knee [4–11]. The impact of such oral treatments, especially NSAIDs, on OA disease progression and outcomes, whether negative or positive, remains at this time an open question that needs to be further explored.

Using the OAI cohort, the objective of this nested case-control study was to explore the potential effects of the most commonly used drug treatments for knee OA and their potential impact on disease progression is not an easy task. However, the use of observational cohorts provides a real-life scenario [8, 10, 11]. The Osteoarthritis Initiative (OAI) cohort presents several advantages for such purpose owing to its size, duration, and very large amount of comprehensive demographic and clinical information available on the study participants, including drug treatment. Structural changes are also assessed by imaging using knee x-rays and magnetic resonance imaging (MRI). The latter has proven to be extremely reliable, sensitive, and very useful for studying disease outcomes [10–15]. Joint replacement is considered a clinically relevant disease outcome in knee OA, which is related to both disease symptoms and structural damage [14–18]. Using the OAI cohort, the objective of this nested case-control study was to explore the potential effects of the most commonly used drug treatments for knee OA, while controlling for the most relevant confounding risk factors on the occurrence of knee replacement (KR). One of the main reasons for choosing a nested case-control design was that, in addition to the robustness of this approach, the exposure to oral OA therapies could be measured in different time windows before the KR.

Methods
Study population
Participants were selected from the OAI database, which is publicly available at https://oai.epi-ucsf.org/datarelease/. The OAI established and maintains a natural history database for knee OA that includes clinical evaluation data and radiological and magnetic resonance (MR) images of 4796 (including the controls) men and women aged 45–79 years at the time of enrolment (cohort entry) between February 2004 and May 2006. The participants selected for the study were from both the progression and the incidence subcohorts. In brief, the participants in the progression subcohort (n = 1389) were subjects with symptomatic tibiofemoral knee OA at baseline who had both of the following in at least one knee at baseline: frequent knee symptoms in the past 12 months defined as “pain, aching or stiffness in or around the knee on most days” for at least 1 month during the past 12 months, and radiographic tibiofemoral knee OA, defined as definite tibiofemoral osteophytes (Osteoarthritis Research Society International [OARSI] atlas grades 1–3), equivalent to Kellgren-Lawrence (KL) grade ≥2 on the fixed-flexion radiograph. The participants in the incidence subcohort (n = 3285) did not have symptomatic knee OA, as defined above, in either knee at baseline. However, they had characteristics that placed them at increased risk of developing symptomatic knee OA during the study. The specific eligibility risk factor criteria for the incidence subcohort were: knee symptoms in a native knee in the past 12 months; being overweight defined using gender and age-specific cut-off points for weight; knee injury defined as a history of knee injury causing difficulty walking for at least a week; knee surgery including meniscal and ligamentous repairs and unilateral total KR for OA; family history defined as a knee replacement for OA in a biological parent or sibling; Heberden’s nodes; repetitive knee bending at work or outside work; and age 70 to 79 years.

In this nested case-control study, participants are defined as subjects presenting a first occurrence of a KR procedure between February 2004 and October 2015. The date on which the KR was reported is defined as the index date. For each case, up to four control subjects [19] without a history of KR before the index date were matched for age (± 1 year), gender, and index date information on income level (± 40,000USD), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain (± 10%), KL grade (same grade), and duration of follow up. Subjects who had missing information on KR or matching variables were excluded.

Definition of exposure to oral OA therapies
The oral OA therapies included acetaminophen, NSAIDs, cyclooxygenase-2 (COX-2) inhibitors, narcotics, and glucosamine/chondroitin sulfate. The information concerning the use of these therapies was obtained from the medical history in the OAI database (typical question: “During the past 6 months (or 30 days), did you use (specific therapy) for joint pain or arthritis on most days?”) For the primary objective, exposure to each of these classes of oral OA therapies was
measured within the 3 years preceding the index date. Exposure was defined as the percentage (%) of all available follow ups at which the subjects reported currently using, at the time of the query, oral OA therapies. Hence, categories of exposure were defined as “no exposure”, “exposure of 1–79%”, and “exposure of 80% or more”. For the secondary objectives, different time periods were employed to measure the exposure to oral OA therapies: 2 years, 4 years, and 5 years before the index date. Subjects who had missing information on exposure to oral OA therapies were excluded.

Covariates
The covariates were race, education level, body mass index (BMI), WOMAC scores (stiffness, function, total), knee injury and osteoarthritis outcome scores (KOOS) (pain, symptoms, and quality of life (QoL)), joint space width (JSW), cartilage volume, bone marrow lesions (BML) size, and presence of meniscal extrusion. The WOMAC [20] and KOOS [21] questionnaires are self-administered: higher WOMAC scores and lower KOOS scores indicate more pain/symptoms and greater functional impairment. Covariates were measured at the index date or at the last available visit before the index date.

Clinical and demographics data
The clinical data were extracted from the OAI database. These included variables used for the matching (age, gender, income level, WOMAC pain, KL), covariates, and arthritis drug treatment taken by the patients, which included acetaminophen, NSAIDs, COX-2 inhibitors, narcotics, and glucosamine/chondroitin sulfate.

Imaging characteristics
The KL grade and the JSW data were obtained from the OAI database (central reading). The MR images were acquired from 3.0 T apparatus (Magnetom Trio, Siemens) at the four OAI clinical centers using a double-echo steady-state imaging protocol. Fully automated and validated quantitative MRI technology was used to assess the cartilage volume [12, 22] and the BMLs [23], and a validated scoring method for the meniscal extrusion [24].

Cartilage volume was analyzed in the knee (femur and plateau) and in the medial and lateral compartments. The change over time was assessed as previously described [12]. Quantitative BML assessment was expressed as a percentage (%) of the lesion in the bone volume in each region of interest [23]. Meniscal extrusion was scored as absence or presence of partial or complete extrusion detected in any of the three segments of the meniscus [24, 25].

Statistical analyses
Descriptive analyses of sociodemographic and clinical characteristics were conducted for case and control patients. These included matching variables (gender and, at index date, age, income level, WOMAC pain, and KL grade), the aforementioned covariates, and exposure to the different classes of oral OA therapies in the 3 years prior to KR. Proportions were calculated for categorical variables, and median and interquartile range (IQR) for continuous variables.

The association between the occurrence of KR and sociodemographic/clinical characteristics (not those used in the matching between cases and controls) was measured using crude conditional logistic regression. An adjusted regression model including significant covariates and pertinent clinical variables was employed to determine the association between exposure to oral OA therapies and occurrence of KR. Odds ratios (OR) and 95% confidence interval (CI) were calculated. Only data with sufficient patient number (n > 10) per time exposure were analyzed and presented. A two-tailed p value <0.05 was considered significant. All statistical analyses were performed using SAS software, V.9.3 (SAS Institute, Cary, NC, USA).

Results
Of the 4674 participants from the incidence and progression subcohorts enrolled in the OAI, 393 had a KR during the follow up. After exclusions for follow up less than 1 year, missing information for matching variables, or no possible match with at least one control, a total of 218 cases were matched to 540 controls for age, gender, income level, WOMAC pain, KL grade, and duration of follow up (Fig. 1).

Characteristics at index date
For the cases (Table 1) the mean age was 68.9 years, 60.6% were female, and the median (IQR) time from cohort entry to having a KR was 4.3 years (1.0–8.9). The majority of cases and controls were white/Caucasian, had an income level greater than $50,000, and had either some college education or a graduate degree. The proportion of cases with a BMI of 27 kg/m² or higher was 75% compared to 71% in controls (Table 2). Compared to controls, cases had higher WOMAC scores (except stiffness), smaller joint space width (JSW), and globally had more BMLs in the knee. Cases and controls had similar characteristics in terms of cartilage volume and meniscal extrusion.

Exposure to narcotics and glucosamine/chondroitin sulfate treatment in the 3 years prior to index date was similar between cases and controls (Table 3). Cases were, however, numerically more exposed to acetaminophen, NSAIDs, and COX-2 inhibitors. Due to absence of specific NSAID description in the OAI database, it was not possible to analyze the effects of the different NSAIDs separately.
Occurrence of KR
The risk of KR occurrence (Table 4) was significantly greater in participants who were white/Caucasian, had a BMI of 27 kg/m² or higher, and had higher WOMAC scores (function, stiffness, total). The KOOS score (pain, symptoms, QoL) was significantly associated with KR occurrence.

Table 5 presents the adjusted OR of KR occurrence for both primary and secondary analyses according to each class of the oral OA therapies. In the primary analysis (exposure measured in the 3 years prior to index date), none of the oral OA therapeutic classes was significantly associated with the occurrence of KR. Secondary analyses (Table 5) were performed to evaluate the impact of varying time windows of exposure on the occurrence of KR in the adjusted regression analyses. KR occurrence was not associated with exposure to any of the oral OA therapies.

Discussion
This study demonstrated, using the OAI database and a nested case-control study design, that exposure to some of the most commonly used oral OA therapies, i.e. acetaminophen, NSAIDs, COX-2 inhibitors, narcotics, or glucosamine/chondroitin sulfate, in a range of 2–5 years, was not associated with the occurrence of KR when compared to no exposure to such medications. However, a number of risk factors were identified as being linked to KR, including race, level of symptoms, and BMI.
Our study also revealed that the oral medications studied had a "neutral" effect on KR while controlling for the most important confounding factors known to promote such occurrences: demographics, socioeconomic status, symptom severity, radiographic grading, and structural changes assessed by quantitative MRI. These results are in contrast to those of Hafezi-Nejad et al. [11], also using the same OAI cohort, showing that long-term use of analgesics comprising NSAIDs, acetaminophen, and narcotics alone or in combination may be associated with radiographic progression of knee OA and increased risk of KR. Similar results on the potential deleterious effects of NSAIDs on the evolution of OA structural changes and disease outcome have already been suggested. Early studies based on the radiographic evaluation of disease progression (joint space narrowing (JSN)) in patients with OA treated with NSAIDs reported a negative impact of long-term use of diclofenac or indomethacin in hip and knee OA [4–8]. Another report on the effects of regular use of prescription NSAID treatment in patients with knee OA identified a reduction in JSN compared to non-users over a 4-year follow-up period [10], although the difference between groups was not statistically significant. However, recent observational studies and randomized controlled trials in patients with knee OA using MRI technology to assess disease progression have shown that treatment with NSAIDs such as naproxen or celecoxib (a cyclooxygenase-2 (COX-2) selective inhibitor) has a neutral effect on cartilage loss [26, 27]. Studies from our group, also using MRI technology, and the participants from the incidence and progression subcohorts of the Osteoarthritis Initiative (OAI) database have also explored the effects of NSAIDs/analgesics and glucosamine/chondroitin sulfate on disease progression by assessing the change in cartilage volume [12, 13]. The findings of these studies showed that the extent of progression of cartilage volume loss was driven by disease severity and meniscal extrusion. NSAID/analgesic treatment had no significant effect on cartilage volume loss. In the latter study [13], glucosamine/chondroitin sulfate treatment reduced the cartilage volume loss in participants with meniscal extrusion regardless of whether or not they were receiving NSAID/analgesic treatment.

Interestingly, the findings of Hafezi-Nejad et al. [11] were also not confirmed in the study of Lapane et al. [10] using the same OAI cohort and exploring the effects of long-term use of NSAIDs on knee OA progression also using x-rays. The greater loss of JSW in the NSAID users compared to the non-users was not statistically significant. However, recent studies based on the radiographic evaluation of disease progression (joint space narrowing (JSN)) in patients with OA treated with NSAIDs reported a negative impact of long-term use of diclofenac or indomethacin in hip and knee OA [4–8]. Another report on the effects of regular use of prescription NSAID treatment in patients with knee OA identified a reduction in JSN compared to non-users over a 4-year follow-up period [10], although the difference between groups was not statistically significant. However, recent observational studies and randomized controlled trials in patients with knee OA using MRI technology to assess disease progression have shown that treatment with NSAIDs such as naproxen or celecoxib (a cyclooxygenase-2 (COX-2) selective inhibitor) has a neutral effect on cartilage loss [26, 27]. Studies from our group, also using MRI technology, and the participants from the incidence and progression subcohorts of the Osteoarthritis Initiative (OAI) database have also explored the effects of NSAIDs/analgesics and glucosamine/chondroitin sulfate on disease progression by assessing the change in cartilage volume [12, 13]. The findings of these studies showed that the extent of progression of cartilage volume loss was driven by disease severity and meniscal extrusion. NSAID/analgesic treatment had no significant effect on cartilage volume loss. In the latter study [13], glucosamine/chondroitin sulfate treatment reduced the cartilage volume loss in participants with meniscal extrusion regardless of whether or not they were receiving NSAID/analgesic treatment.
positive as well as negative findings with regard to the potential beneficial or deleterious effects of such drugs on OA structural changes [7, 9], which does not help to settle this debate.

A very important distinction of the present study compared to most others, is the use of a nested case-control design that we chose for a number of reasons. The well-recognized advantage of such a study design is that it allowed us to assess patients’ characteristics as risk factors to be evaluated at the very date of KR surgery. This is in sharp contrast to a cohort study design, in which the patient profiles are assessed at entry (baseline) into

| Table 2 Clinical characteristics at index date | Knee replacement | Control (n = 540) |
|-----------------------------------------------|-----------------|-----------------|
| Case (n = 218)                                |                 |                 |
| BMI ≥ 27 kg/m², % (n)                         |                 |                 |
| WOMAC, median (IQR)                           |                 |                 |
| Pain (0–20)                                   |                 |                 |
| Function (0–68)                               |                 |                 |
| Stiffness (0–10)                              |                 |                 |
| Total (0–98)                                  |                 |                 |
| KOOS, median (IQR)                            |                 |                 |
| Pain (0–100)                                  |                 |                 |
| Symptoms (0–100)                              |                 |                 |
| QoL (0–100)                                   |                 |                 |
| Kellgren-Lawrence grade, % (n)                |                 |                 |
| 0                                             | 1.4% (3)        | 1.7% (9)        |
| 1                                             | 3.7% (8)        | 3.7% (20)       |
| 2                                             | 19.3% (42)      | 23.9% (129)     |
| 3                                             | 31.6% (69)      | 29.8% (161)     |
| 4                                             | 44.0% (96)      | 40.9% (221)     |
| JSW (mm), median (IQR)                        |                 |                 |
| Cartilage volume (mm³), median (IQR)          |                 |                 |
| Global knee                                   | 2.0 (0.8–4.6)  | 2.8 (1.1–4.6)  |
| Medial compartment                            | 11,037 (9127 - 13,634) | 11,058 (9351 - 13,508) |
| Lateral compartment                           | 5127 (3971 - 6482) | 5219 (4176 - 6502) |
| BML                                           | 6028 (4864 - 7480) | 6043 (4970 - 7265) |
| Global                                        |                 |                 |
| Median (IQR)                                  | 2.0 (0.6–4.4)  | 1.7 (0.4–3.8)  |
| BML ≥ 1%, % (n)                               | 65.7% (132)     | 61.5% (314)     |
| Medial compartment                             |                 |                 |
| Median (IQR)                                  | 0.014 (0.0–0.058) | 0.021 (0.0–0.057) |
| BML ≥ 1%, % (n)                               | 34.9% (76)      | 42.2% (228)     |
| Lateral compartment                            |                 |                 |
| Median (IQR)                                  | 0.005 (0.0–0.025) | 0.0 (0.0–0.018)  |
| BML ≥ 1%, % (n)                               | 23.9% (52)      | 20.7% (112)     |
| Meniscal extrusion, % (n)                     |                 |                 |
| 39.5% (85)                                    |                 | 38.5% (205)     |

Data shown are proportion of patients (%), number of patients (n), or median (interquartile range (IQR)).

BMI body mass index, BML bone marrow lesions, JSW joint space width, KOOS Knee injury and Osteoarthritis Outcome Score, QoL quality of life, WOMAC Western Ontario and McMaster Universities Osteoarthritis Index.
Another important issue of our study is the use of KR as the sole marker of disease progression, which has already been established as a valid outcome in a number of studies [11, 15–18, 30, 31]. Indeed, there is a general consensus that MRI parameters assessed in knee OA, such as the medial compartment cartilage volume/thickness, can predict outcomes such as KR in a consistent manner [14–18]. However, findings of the present and previous studies [17, 29, 32] also indicate that the ultimate decision of the patient to undergo KR is likely multifactorial in origin and involves a large number of confounding factors that extend well beyond the severity of knee OA structural changes. In our study, however, the cartilage volume at index (KR) time as assessed by MRI was similar in both groups, suggesting that over time the factors leading to progression of cartilage volume loss up to the KR were globally balanced in both groups. One must be cautious with the interpretation that drug treatment that can accelerate disease progression, if true, may have exerted its effects on both control and KR groups. Although the effect of drug treatment on rate of disease progression was not assessed in this study, several previous studies have addressed this very specific issue, a number of which used the OAI cohort [10–13]. Based on the findings of these studies, one may be tempted to conclude that factors in addition to disease progression are very likely to influence the patient’s decision to undergo KR. The results of the present study showing that JSW at index time was not linked to the occurrence of KR certainly support this view.

In the present study we also explored the cumulative exposure to oral OA therapies measured in different time windows, from 2 to 5 years before the date of the KR, to evaluate their impact in different scenarios to yield robustness of our analyses. Interestingly, these analyses did not show any time frame trends, shorter or longer, that would significantly promote greater risk of KR. Windows of 6 to 8 years of exposure to oral OA therapies were also considered, but the number of available patients was too small for statistical inference. The results of the study are reassuring and clinically relevant since they tackle the confounding role of any oral intervention to treat pain as a “last resort” prior to inevitable surgery, creating a spurious association between drug usage and the risk of KR, in turn suggesting a deleterious role of the medication via a channeling bias. Moreover, presence of severe comorbidities, frequently encountered with severe OA, are usually perceived by orthopedic surgeons as promoting perioperative risks and, as such, they are less inclined to recommend surgery for these patients. These same comorbidities may also preclude the use of NSAIDs and narcotics for these “morbid” patients, hence yielding spurious correlation between use of these medications and more KRs being performed.

Our study has a number of strengths. First, it was conducted using the large OAI database, representative of a North American population with fairly open access to usual care for knee OA, including KR, based on patient and physician preferences in a context of a real-world scenario. Second, to our knowledge, this is among the first studies that allowed stratification of risk of KR by

### Table 3 Exposure to different oral OA therapies in the 3 years prior to index date

| Oral OA therapies, % (n) | Knee replacement Case (n = 161)a | Control (n = 360)a |
|-------------------------|---------------------------------|-------------------|
| Acetaminophen           |                                 |                   |
| No exposure             | 70.2% (113)                     | 75.0% (270)       |
| Exposure 1–79%          | 26.7% (43)                      | 22.5% (81)        |
| Exposure ≥ 80%          | 3.1% (5)                        | 2.5% (9)          |
| NSAIDs                  |                                 |                   |
| No exposure             | 37.3% (60)                      | 51.4% (185)       |
| Exposure 1–79%          | 38.5% (62)                      | 33.3% (120)       |
| Exposure ≥ 80%          | 24.2% (39)                      | 15.3% (55)        |
| COX-2 inhibitors        |                                 |                   |
| No exposure             | 86.3% (139)                     | 91.1% (328)       |
| Exposure 1–79%          | 7.5% (12)                       | 4.7% (17)         |
| Exposure ≥ 80%          | 6.2% (10)                       | 4.2% (15)         |
| Narcotics               |                                 |                   |
| No exposure             | 88.8% (143)                     | 89.7% (323)       |
| Exposure 1–79%          | 10.0% (16)                      | 7.5% (27)         |
| Exposure ≥ 80%          | 1.2% (2)                        | 2.8% (10)         |
| Glucosamine/chondroitin sulfate |                   |                   |
| No exposure             | 45.3% (73)                      | 45.8% (165)       |
| Exposure 1–79%          | 23.0% (37)                      | 23.1% (83)        |
| Exposure ≥ 80%          | 31.7% (51)                      | 31.1% (112)       |

Data shown are proportion of patients (%) and number of patients (n)

COX-2 cyclooxygenase-2, NSAIDs non-steroidal anti-inflammatory drugs, OA osteoarthritis

aOf the total number of cases (218) and controls (540), 161 cases and 360 controls had complete information for the 3 years prior to index date

the cohort [10, 11, 30]. During the elapsed time between cohort entry and date of KR, which may be several years in most cases, the profiles of patients who undergo KR, such as symptoms, function, and medication usage, may change substantially. The nested case-control design thus allowed evaluation of patient characteristics that best represent the patient status at the time of the KR occurrence, not several years before. It is therefore important to recognize that such a study design will probably impact findings when assessing a relationship between drug exposure and risk of KR, in turn potentially explaining results different from those of recent longitudinal cohort study designs using the same OAI database [11], as mentioned previously.
as poor choices may yield very different conclusions. Always an important issue for nested case-control designs, is reassuring, as control selection is critical. Last, the excellent matching yielded from our control selection strategy, as shown in the baseline characteristics comparison, is reassuring, as control selection is crucial when trying to establish a “cause-effect” response using categories we have coined levels of “exposure”: no exposure, occasional (exposure 1–79%), or regular (≥80%) medication usage, acknowledging such limitation.

The study design also did not allow comprehensive assessment of the influence of confounding factors, as some of the data used were only available at baseline and not at the index time of KR. Despite attempts to adjust for several confounders, causal interpretation of the findings is restricted, and residual confounding must be considered when interpreting the results.

Furthermore, this study focused on patients with severe OA in need of surgery; other beneficial or deleterious associations with chronic use of oral OA drugs and subclinical structural damage, as seen using quantitative MRI for example, may be found in subjects with less severe OA.

It was also impossible to assess the knee OA disease duration since onset of symptoms or date of OA diagnosis was not collected in the OAI dataset. Knee OA duration could have a significant impact on the cumulative and progressive joint damage, but we were unfortunately unable to control for it.

Statistical power may also be an issue since, by selecting subjects that had a KR but also had almost all demographic, clinical and MRI information, patient number was reduced from more than 4674 subjects to a mere 218 cases of KR, which is somewhat limited for performing multivariate analyses.

Finally, actual KR occurrences may be considered by some as an inadequate outcome for a comprehensive severe progressive OA definition. In fact, in the present work, we did not assess knee OA progression using imaging outcomes such as JSW or cartilage thickness/volume loss prior to the KR. The rate of such progression might accelerate while nearing the KR occurrence, which may or may not be associated with oral OA medication use. However, as already mentioned, the cartilage volume at index (KR) time as assessed by MRI was similar in both groups, suggesting that over time the factors leading to progression of cartilage volume loss up to the KR were globally balanced in both groups. Despite the great clinical success of KR, the criteria on which surgery is performed are not uniform. Apart from symptoms and radiographic

Limitations of this study include the fact that it did not allow identification of any specific drug class. For instance, the impossibility of defining a specific NSAID name within the database is a limitation as some NSAIDs, such as for example indomethacin, may prove to be more deleterious than others [4–9]. The data provided on drug usage were obtained by self-administered questionnaire and not by a traditional pill count, which is used to assess adherence and persistence to medication in most clinical trials. This could underestimate true prolonged and cumulative usage of these medications. We have nonetheless tried to establish a “dose-effect” response using categories we have coined levels of “exposure”: no exposure, occasional (exposure 1–79%), or regular (≥80%) medication usage, acknowledging such limitation.

As for example indomethacin, may prove to be more deleterious than others [4–9]. The data provided on drug usage were obtained by self-administered questionnaire and not by a traditional pill count, which is used to assess adherence and persistence to medication in most clinical trials. This could underestimate true prolonged and cumulative usage of these medications. We have nonetheless tried to establish a “dose-effect” response using categories we have coined levels of “exposure”: no exposure, occasional (exposure 1–79%), or regular (≥80%) medication usage, acknowledging such limitation.

The study design also did not allow comprehensive assessment of the influence of confounding factors, as some of the data used were only available at baseline and not at the index time of KR. Despite attempts to adjust for several confounders, causal interpretation of the findings is restricted, and residual confounding must be considered when interpreting the results.

Furthermore, this study focused on patients with severe OA in need of surgery; other beneficial or deleterious associations with chronic use of oral OA drugs and subclinical structural damage, as seen using quantitative MRI for example, may be found in subjects with less severe OA.

It was also impossible to assess the knee OA disease duration since onset of symptoms or date of OA diagnosis was not collected in the OAI dataset. Knee OA duration could have a significant impact on the cumulative and progressive joint damage, but we were unfortunately unable to control for it.

Statistical power may also be an issue since, by selecting subjects that had a KR but also had almost all demographic, clinical and MRI information, patient number was reduced from more than 4674 subjects to a mere 218 cases of KR, which is somewhat limited for performing multivariate analyses.

Finally, actual KR occurrences may be considered by some as an inadequate outcome for a comprehensive severe progressive OA definition. In fact, in the present work, we did not assess knee OA progression using imaging outcomes such as JSW or cartilage thickness/volume loss prior to the KR. The rate of such progression might accelerate while nearing the KR occurrence, which may or may not be associated with oral OA medication use. However, as already mentioned, the cartilage volume at index (KR) time as assessed by MRI was similar in both groups, suggesting that over time the factors leading to progression of cartilage volume loss up to the KR were globally balanced in both groups. Despite the great clinical success of KR, the criteria on which surgery is performed are not uniform. Apart from symptoms and radiographic

### Table 4 Association between sociodemographic/clinical characteristics at the index date and occurrence of knee replacement

| Characteristic                  | Crude OR | 95% CI | p-value |
|--------------------------------|----------|--------|---------|
| Race: white or Caucasian (reference other race) | 1.84     | (1.13–2.99) | 0.015   |
| Education level: college graduate or above (reference less than college graduate) | 0.95     | (0.65–1.38) | 0.778   |
| BMI ≥ 27 kg/m² (reference < 27 kg/m²) | 1.65     | (1.06–2.58) | 0.027   |
| WOMAC Function | 1.04     | (1.02–1.06) | < 0.001 |
| WOMAC Stiffness | 1.25     | (1.12–1.40) | 0.001   |
| WOMAC Total | 1.03     | (1.02–1.04) | < 0.001 |
| KOOS Pain | 0.98     | (0.97–0.99) | < 0.001 |
| KOOS Symptoms | 0.98 | (0.97–0.99) | < 0.001 |
| KOOS QoL | 0.97     | (0.96–0.98) | < 0.001 |
| X-ray (JSW) | 0.93     | (0.85–1.01) | 0.092   |
| MRI BML | 1.04     | (0.99–1.09) | 0.144   |
| By increase of 1% | 1.41     | (0.95–2.11) | 0.091   |
| BML ≥ 1% (reference < 1%) | 1.18     | (0.80–1.73) | 0.404   |
| Meniscal extrusion (reference no extrusion) | 1.81     | (1.18–2.80) | 0.001   |

**BMI** body mass index, **BML** bone marrow lesion, **CI** confidence interval, **JSW** joint space width, **KOOS** Knee injury and Osteoarthritis Outcome Score, **OR** odds ratio, **QoL** quality of life, **WOMAC** Western Ontario and McMaster Universities Osteoarthritis Index.

Excluding characteristics used in the matching between cases and controls (i.e. age, gender, income, WOMAC pain, and KL grade).

Crude conditional logistic regression. Bold indicates statistical significance (p < 0.05)

extent of exposure to oral OA medication versus no exposure, which is paramount when trying to establish a cause-effect of medication on an ultimate outcome such as KR. We chose a priori a 3-year window of oral OA medication exposure based on a clinical rationale and the design of previous studies [17, 30, 31]. Third, per the OAI design, we have great certainty about the knee OA diagnosis and its KR indication based on detailed information on demographics, symptoms, imaging, and drug use for both patients and their matched controls. Fourth, medical data were routinely recorded by investigators including rheumatologists and orthopedic surgeons without a study hypothesis, yielding a “nested” case-control study, hence minimizing the possibility of recall bias, which plagues conventional retrospective chart review studies. Last, the excellent matching yielded from our control selection strategy, as shown in the baseline characteristics comparison, is reassuring, as control selection is always an important issue for nested case-control designs as poor choices may yield very different conclusions.
Table 5 Association between exposure to different oral osteoarthritis therapies and occurrence of knee replacement

|                                      | Acetaminophen | NSAIDs | COX-2 inhibitors | Narcotics | Glucosamine/chondroitin sulfate |
|--------------------------------------|---------------|--------|------------------|-----------|---------------------------------|
|                                      | n  | OR^b | 95% CI | p^c | n | OR^b | 95% CI | p^c | n | OR^b | 95% CI | p^c | n | OR^b | 95% CI | p^c |
| **Primary analysis**                 |    |      |        |    |    |      |        |    |    |      |        |    |    |      |        |    |
| In the 3 years prior to index date   | (n = 521: 161 KR/360 controls) |    |      |    |    |      |        |    |    |      |        |    |    |      |        |    |
| Exposure 1–79%^a                      | 124 | 1.09 | (0.66–1.78) | 0.745 | 313 | 1.05 | (0.64–1.72) | 0.839 | 68 | 1.13 | (0.48–2.67) | 0.784 | 67 | 1.00 | (0.48–2.09) | 0.995 |
| Exposure ≥ 80%^a                      | 14  | 1.11 | (0.30–4.09) | 0.872 | 44  | 1.66 | (0.93–2.95) | 0.086 | 21  | 1.15 | (0.47–2.83) | 0.761 | ND | ND      |        |    |
| In the 2 years prior to index date   | (n = 642: 193 KR/449 controls) |    |      |    |    |      |        |    |    |      |        |    |    |      |        |    |
| Exposure 1–79%^a                      | 210 | 1.10 | (0.66–1.84) | 0.722 | 369 | 0.96 | (0.60–1.54) | 0.853 | 88  | 1.40 | (0.57–3.48) | 0.465 | 77  | 1.19 | (0.54–2.58) | 0.670 |
| Exposure ≥ 80%^a                      | 20  | 1.46 | (0.69–3.11) | 0.322 | 58  | 1.41 | (0.88–2.26) | 0.159 | 27  | 1.18 | (0.55–2.52) | 0.671 | ND | ND      |        |    |
| In the 4 years prior to index date   | (n = 363: 121 KR/242 controls) |    |      |    |    |      |        |    |    |      |        |    |    |      |        |    |
| Exposure 1–79%^a                      | 113 | 1.34 | (0.74–2.41) | 0.333 | 234 | 1.40 | (0.78–2.52) | 0.256 | 50  | 1.63 | (0.64–4.13) | 0.303 | 50  | 1.43 | (0.62–3.33) | 0.405 |
| Exposure ≥ 80%^a                      | ND  | ND   | ND      |    |    |      |        |    |    |      |        |    |    |      |        |    |
| In the 5 years prior to index date   | (n = 228: 82 KR/146 controls) |    |      |    |    |      |        |    |    |      |        |    |    |      |        |    |
| Exposure 1–79%^a                      | 60  | 1.38 | (0.66–2.88) | 0.397 | 110 | 1.88 | (0.85–4.20) | 0.121 | 18  | 1.35 | (0.41–4.49) | 0.623 | 33  | 1.19 | (0.48–2.93) | 0.706 |
| Exposure ≥ 80%^a                      | 15  | 1.60 | (0.44–6.35) | 0.457 | 45  | 2.27 | (0.90–5.71) | 0.081 | ND | ND | ND      |        |    |    |      |        |

CI confidence interval, COX-2 cyclooxygenase-2, KR knee replacement, ND not determinable, n value too small, NSAIDs non-steroidal anti-inflammatory drugs, OA osteoarthritis, OR odds ratio

^aCompared to the “no exposure” category
^bAdjusted for race, body mass index, other medication for pain, joint space width, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) stiffness, meniscal extrusion, bone marrow lesions, and Knee injury and Osteoarthritis Outcome Score (KOOS)
^cConditional logistic regression

Dorais et al. Arthritis Research & Therapy (2018) 20:172
status, surgical indication depends on willingness, comorbidity, access to health care, socioeconomic status, etc. A validated KR “indication” as a clinical outcome, as suggested by the OARSI/Outcome Measures in Rheumatology (OMERACT) group \[32\] could help in that regard for future studies.

Conclusion
The present study indicates that patients chronically taking the most commonly used oral OA therapies do not have an increased risk of KR. In an era of OA therapeutic choice paucity, our study is somewhat reassuring and repositions chronic symptomatic OA treatment as safe. However, longer-term and controlled studies and safety assessments should also be performed in the context of longitudinal follow up to further probe our initial findings.

Acknowledgements
The authors thank the OAI participants and Coordinating Center for their work in generating the clinical and radiological data from the OAI cohort and for making them publicly available. The OAI is a public-private partnership comprising five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript was prepared using an OAI public use data set and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. We also thank Virginia Wallis for her assistance with the manuscript preparation.

Funding
The study conception was funded by grants from Bioibérica (Barcelona, Spain), the Osteoarthritis Research Unit and the Chair in Osteoarthritis of the University of Montreal (Montreal, Quebec, Canada).

Availability of data and materials
The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request. Data generated or analyzed during this study are included in this published article and are noted as data not shown.

Authors’ contributions
J-PP and JMP have full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. MD, J-PR, and PD are responsible for statistical analyses for this study. Study concept and design: MD, JMP, J-PR, and J-PP. Acquisition of data: MD, JMP, PD, and J-PP. Drafting of the manuscript: MD, JMP, J-PR, and J-PP. Critical revision of the manuscript for important intellectual content: MD, JMP, J-PR, PD, and J-PP. JMP and J-PP obtained funding. Study supervision: JMP and J-PP. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
Although funded in part by Bioibérica (see Funding above), the sponsor had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript. The sponsor had no access to the data and did not perform any of the study analysis. Drs. Martel-Pelletier and Pelletier are consultants for Bioibérica and shareholders in ArthroLab Inc. M Dorais and Dr. Raynauld are consultants for ArthroLab Inc. None of the authors are part of the OAI investigative team.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Statsciences Inc., Notre-Dame-de-l’Ile-Perrot, Quebec, Canada. 2Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Quebec, Canada.

Received: 21 February 2018 Accepted: 29 June 2018
Published online: 07 August 2018

References
1. Hagen KB, Smidt-Lundg, Moe RH, Grotle M, Kjeken I, Kvien TK. The evidence for non-pharmacological therapy of hand and hip OA. Nat Rev Rheumatol. 2009;5(9):517–9.
2. FDA Drug Safety Communication. FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes (7-9-2015). Available at: https://www.fda.gov/Drugs/DrugSafety/ucm451800.htm (Accessed 23 May 2018).
3. Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010;170(22):1968–76.
4. Milner JC. Osteoarthritis of the hip and indomethacin. J Bone Joint Surg (Br). 1972;54B:752–6.
5. Runnening H. Indomethacin hips. Acta Orthop Scand. 1977;48:556–61.
6. Huskisson EC, Berry H, Gishen P, Jubb RW, Whitehead J. Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee. LINK study group. Longitudinal investigation of nonsteroidal antiinflammatory drugs in knee osteoarthritis. J Rheumatol. 1995;22:1941–6.
7. Ding C. Do NSAIDs affect the progression of osteoarthritis? Inflammation. 2002;26(3):139–42.
8. Rejman M, Berna-Zeinstra SM, Pols HA, Koers BW, Stricker BH, Hazes JM. Is there an association between the use of different types of nonsteroidal antiinflammatory drugs and radiologic progression of osteoarthritis? The Rotterdam study. Arthritis Rheum. 2005;52(10):3137–42.
9. Hauser RA. The acceleration of articular cartilage degeneration in osteoarthritis by nonsteroidal anti-inflammatory drugs. J Prolotherapy. 2010;2(1):305–22.
10. Lapane KL, Yang S, Dibben JB, Liu SH, Dube CE, McAlindon TE, Eaton CB. Effects of prescription nonsteroidal antiinflammatory drugs on symptoms and disease progression among patients with knee osteoarthritis. Arthritis Rheumatol. 2015;67(3):724–32.
11. Hafezi-Nejad N, Guermazi A, Roemer FW, Eng J, Zikria B, Demehri S. Long-term use of analgesics and risk of osteoarthritis progressions and knee replacement: propensity score matched cohort analysis of data from the osteoarthritis initiative. Osteoarthr Cartil. 2016;24(4):597–604.
12. Martel-Pelletier J, Roubille C, Abram F, Hochberg MC, Dorais M, Delorme P, Raynauld JP, Pelletier JP. First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. Ann Rheum Dis. 2015;74(3):547–56.
13. Roubille C, Martel-Pelletier J, Abram F, Dorais M, Delorme P, Raynauld JP, Pelletier JP. Impact of disease treatments on the progression of knee osteoarthritis structural changes related to meniscal extrusion: data from the OAI progression cohort. Semin Arthritis Rheum. 2015;45(3):257–67.
14. Eckstein F, Boudreau RM, Wang Z, Hannon MJ, Wirth W, Cotofana S, Guermazi A, Roemer F, Nevitt M, John MR, et al. Trajectory of cartilage loss...
within 4 years of knee replacement—a nested case-control study from the osteoarthritis initiative. Osteoarthr Cartil. 2014;22(10):1542–9.

15. Eckstein F, Kwoh CK, Boudreau RM, Wang Z, Hannon MJ, Cotofana S, Hudelmaier MJ, Wirth W, Guermazi A, Nevidt MC, et al. Quantitative MRI measures of cartilage predict knee replacement: a case-control study from the osteoarthritis initiative. Ann Rheum Dis. 2013;72(5):707–14.

16. Pelletier JP, Cooper C, Peterfy C, Reginster JY, Brandi ML, Bruyere O, Chapurlat R, Cicuttini F, Conaghan PG, Doherty M, et al. What is the predictive value of MRI for the occurrence of knee replacement surgery in knee osteoarthritis? Ann Rheum Dis. 2013;72(10):1594–604.

17. Raynauld JP, Martel-Pelletier J, Harauzi B, Choquette D, Dorais M, Wildi LM, Abram F, Pelletier JP. Risk factors predictive of joint replacement in a 2-year multicentre clinical trial in knee osteoarthritis using MRI: results from over 6 years of observation. Ann Rheum Dis. 2011;70(8):1382–8.

18. Cicuttini FM, Jones G, Forbes A, Wluka AE. Rate of cartilage loss in patients with symptomatic knee osteoarthritis? Arthritis Research & Therapy. 2008;10(1):R21.

19. Breslow NE, Day NE. Chapter 7. Design considerations. Table 7.9. In: Breslow NE, Day NE, editors. Statistical methods in cancer research. Volume II—the design and analysis of cohort studies. Oxford: IARC Sci Publ. 1987. p. 297–300.

20. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15:1833–40.

21. Roos EM, Roos HP, Lohmander LS, Ekdahl C, Beynnon BD. Knee injury and osteoarthritis outcome score (KOOS)—development of a self-administered outcome measure. J Orthop Sports Phys Ther. 1999;28(2):88–96.

22. Dodin P, Pelletier JP, Martel-Pelletier J, Abram F. Automatic human knee cartilage segmentation from 3D magnetic resonance images. IEEE Trans Biomed Eng. 2010;57:2699–711.

23. Dodin P, Abram F, Pelletier JP, Martel-Pelletier J. A fully automated system for quantification of knee bone marrow lesions using MRI and the osteoarthritis initiative cohort. J Biomed Graph Comput. 2013;3(1):51–65.

24. Berthiaume MJ, Raynauld JP, Martel-Pelletier J, Labonté F, Beaudoin G, Bloch DA, Choquette D, Harauzi B, Altman RD, Hochberg M, et al. Meniscal tear and extrusion are strongly associated with the progression of knee osteoarthritis as assessed by quantitative magnetic resonance imaging. Ann Rheum Dis. 2005;64:556–61.

25. Raynauld JP, Martel-Pelletier J, Berthiaume MJ, Beaudoin G, Choquette D, Harauzi B, Tannenbaum H, Meyer JM, Beary JF, Cline GA, et al. Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients correlation with clinical symptoms and radiographic changes. Arthritis Res Ther. 2006;8(1):R21.

26. Raynauld JP, Martel-Pelletier J, Beaulieu A, Bessette L, Morin F, Choquette D, Harauzi B, Abram F, Pelletier JP. An open-label pilot study evaluating by magnetic resonance imaging the potential for a disease-modifying effect of celecoxib compared to a modeled historical control cohort in the treatment of knee osteoarthritis. Semin Arthritis Rheum. 2010;40(3):185–92.

27. Raynauld JP, Martel-Pelletier J, Bias P, Laufer S, Harauzi B, Choquette D, Beaulieu AD, Abram F, Dorais M, Vignon E, et al. Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. Ann Rheum Dis. 2009;68(9):938–47.

28. Klopf C, de Vries F, Lamahmed A, Mastbergen SC, Leufkens HG, Noort-vander Laan WH, Bijlsma JW, Welsing PM. COX-2-selective NSAIDs and risk of hip or knee replacements: a population-based case-control study. Calcif Tissue Int. 2012;91(6):387–94.

29. Riddle DL, Kong X, Jiranek WA. Two-year incidence and predictors of future knee arthroplasty in persons with symptomatic knee osteoarthritis: preliminary analysis of longitudinal data from the osteoarthritis initiative. Knee. 2009;16(6):494–500.

30. Bruyere O, Pavelka K, Rozet LC, Gatterova J, Giacovelli G, Olejarova M, Derosyi R, Reginster JY. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthr Cartil. 2008;16(2):254–60.

31. Raynauld JP, Pelletier JP, Abram F, Dodin P, Delorme P, Martel-Pelletier J. Long-term effects of glucosamine and chondroitin sulfate on the progression of structural changes in knee osteoarthritis: six-year follow up data from the osteoarthritis initiative. Arthritis Care Res (Hoboken). 2016;68(10):1560–6.